Clinical Trial: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Study Status: Withdrawn
Recruit Status: Withdrawn
Study Type: Interventional

Official Title: A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma

Brief Summary: The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.

Detailed Summary:
Sponsor: Infinity Pharmaceuticals, Inc.

Current Primary Outcome: To determine the safety profile and overall response rate (ORR) of IPI 504 in patients with advanced dedifferentiated liposarcoma. [ Time Frame: Every 6 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: To determine the clinical benefit rate and duration of overall response [ Time Frame: Every 6 weeks ]

Original Secondary Outcome: Same as current

Information By: Infinity Pharmaceuticals, Inc.

Dates:
Date Received: September 1, 2009
Date Started: January 2010
Date Completion: December 2010
Last Updated: April 13, 2015
Last Verified: April 2015